Patients with multiple myeloma who receive autologous peripheral blood stem cell harvest
Conditions
Interventions
Patients are administered meloxicam 10 mg once per day from the 10th day after the administration of the anticancer drug until 2 days before apheresis
Sponsors
Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients who receive their first autologous peripheral blood stem cell harvest 2)Patients who are eligible for apheresis 3)Written informed consent
Exclusion criteria
Exclusion criteria: 1)Patients who are not eligible for apheresis 2)Allergy to meloxicam 3)Patients who cannot take medicine orally on the 10th day after the administration of the anticancer drug 4)Patients with bleeding tendency before treatment 5)Patients who are difficult to maintain platelets more than 20,000/mm3 even if appropriate measures such as platelet transfusion are done 6)Patients with active gastrointestinal ulcer 7)Patients with severe renal dysfunction (G3b or more in GFR classification) 8)Patients with aspirin-induced asthma or a history of aspirin-induced asthma 9)Inadequate condition as diagnosed by primary physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative incidence and severity of bleeding, gastrointestinal ulcer and renal dysfunction and analgesic effect | — |
Secondary
| Measure | Time frame |
|---|---|
| The collection efficiency of hematopoietic stem cells | — |
Countries
Japan
Contacts
Public ContactAiko Igarashi
Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital Hematology division
Outcome results
None listed